Matthew C Baker
Stanford University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Matthew C Baker as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:22 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07025330 · A Study of Efgartigimod in Patients With IgG4-Related DiseaseStanford University · active not recruiting · IgG4-related Disease · principal investigator
- Ph2NCT06868381 · A Trial of Baricitinib in Patients With Cardiac SarcoidosisStanford University · not yet recruiting · Cardiac Sarcoidosis · principal investigator
- Ph2NCT05781451 · Anti-BTLA Agonist Therapy in Subjects With Primary Sjogren's SyndromeStanford University · withdrawn · Primary Sjogren's Syndrome · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:22 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:22 UTC. The ranking covers the 200 most relevant of 5 PubMed records, and a shared surname and initials can bring in a namesake. All 5 on PubMed
- A Randomized, Double-Blind, Sham-Controlled, Clinical Trial of Auricular Vagus Nerve Stimulation for the Treatment of Active Rheumatoid Arthritis.Arthritis Rheumatol · 202339 citationsRCR 5.3
- Autosomal dominant dystonia-plus with cerebral calcifications.Neurology · 200630 citationsRCR 0.8
- A double-blind, placebo-controlled, randomized withdrawal trial of sarilumab for the treatment of glucocorticoid-dependent sarcoidosis.Rheumatology (Oxford) · 202414 citationsRCR 2.4
- Obexelimab for the Treatment of IgG4-Related Disease.N Engl J Med · 2026